Swissmedic accepts review of Takeda and TiGenix ’s file on Cx601

The Swiss Agency for Therapeutic Products (Swissmedic) has accepted a review of Takeda and TiGenix ’s file on investigational compound Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news